<?xml version="1.0" encoding="UTF-8"?>
<p>Eligibility criteria included the following: newly pathologically diagnosed with MCL according to the WHO classification 2001;
 <xref rid="cas13719-bib-0015" ref-type="ref">15</xref> positive staining for cyclin D1 in the nucleus of lymphoma cells; positive for CD5 and CD20 on lymphoma cells by flow cytometry or by immunohistochemistry; age between 20 and 65 years; ECOG performance status (PS) of 0, 1, or 2; clinical stage II with bulky disease, stages III or IV according to the Ann Arbor staging system; lymphoma cells in peripheral blood ≤10 000/μL; no involvement of the central nervous system; at least 1 measurable lymphomatous lesion; no previous history of chemotherapy, radiation therapy, IFN, and/or antibody therapy; adequate organ function; and written, informed consent. Patients were excluded if they had a history of glaucoma, uncontrollable diabetes mellitus, uncontrollable hypertension, hepatitis B virus surface antigens or antibodies to hepatitis C virus, interstitial pneumonia, severe bacterial infection, or another active neoplasm.
</p>
